BridgeBio Oncology Therapeutics (BBOT) investor relations material

Key accomplishments in 2025

• Advanced all three in-house discovered clinical programs targeting RAS and PI3K alpha oncogenes.

• Achieved rapid clinical execution, including IND filing and first patient dosing for 818 within two months.

• Completed a de-SPAC merger, raising $380 million with low redemptions, providing financial runway.

• Set up for 2026 with planned data readouts for all three programs: 8520 (Q1), 10203 (H1), and 11818 (H2).

Scientific and clinical strategy

• Focused on high-level inhibition of RAS, a target mutated in 30% of human tumors, using novel small molecules.

• Developed KRAS inhibitors (8520, 818) and a first-in-class RAS PI3K alpha breaker for selective pathway inhibition.

• 8520 demonstrated 60% confirmed overall response rate and no grade 3 toxicities in early clinical data.

• 10203 designed to avoid hyperglycemia by targeting RAS-dependent PI3K alpha activation, with no HbA1c restrictions in trials.

• 11818 is a non-covalent, pan-KRAS inhibitor selective over H and N, aiming for high inhibition in KRAS mutant tumors.

Upcoming milestones and data expectations

• 8520: Q1 2026 data to include monotherapy dose escalation, safety, and early efficacy in combination with pembrolizumab.

• 10203: H1 2026 data to show monotherapy dose escalation, safety, target engagement, and early combination data in three tumor types.

• 11818: H2 2026 data to focus on activity and therapeutic index in colon, pancreas, and lung KRAS mutant tumors.

• Portfolio-wide evaluation and prioritization planned after all data readouts.